Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARVN NASDAQ:OLMA NASDAQ:OPT NASDAQ:THTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$7.74-0.9%$7.51$5.90▼$29.61$573.40M2.381.33 million shs1.20 million shsOLMAOlema Pharmaceuticals$7.77-2.9%$5.47$2.86▼$13.93$533.29M1.92938,510 shs1.35 million shsOPTOpthea$3.41$3.41$1.79▼$6.30$583.11M1.17N/AN/ATHTXTheratechnologies$3.30+0.6%$3.20$1.12▼$3.31$150.81M0.51344,956 shs696,400 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas0.00%-1.15%+9.32%+4.74%-68.90%OLMAOlema Pharmaceuticals0.00%-6.50%+47.72%+86.33%-37.03%OPTOpthea0.00%0.00%0.00%0.00%+10.00%THTXTheratechnologies0.00%+0.92%+2.48%+33.06%+168.29%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$7.74-0.9%$7.51$5.90▼$29.61$573.40M2.381.33 million shs1.20 million shsOLMAOlema Pharmaceuticals$7.77-2.9%$5.47$2.86▼$13.93$533.29M1.92938,510 shs1.35 million shsOPTOpthea$3.41$3.41$1.79▼$6.30$583.11M1.17N/AN/ATHTXTheratechnologies$3.30+0.6%$3.20$1.12▼$3.31$150.81M0.51344,956 shs696,400 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas0.00%-1.15%+9.32%+4.74%-68.90%OLMAOlema Pharmaceuticals0.00%-6.50%+47.72%+86.33%-37.03%OPTOpthea0.00%0.00%0.00%0.00%+10.00%THTXTheratechnologies0.00%+0.92%+2.48%+33.06%+168.29%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARVNArvinas 2.55Moderate Buy$19.76155.34% UpsideOLMAOlema Pharmaceuticals 2.83Moderate Buy$24.00208.88% UpsideOPTOpthea 2.17Hold$1.33-60.90% DownsideTHTXTheratechnologies 3.00BuyN/AN/ACurrent Analyst Ratings BreakdownLatest THTX, OPT, ARVN, and OLMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025OLMAOlema PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold9/3/2025OLMAOlema PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$22.008/14/2025OLMAOlema PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$28.00 ➝ $29.008/12/2025OLMAOlema PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $21.008/11/2025OLMAOlema PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell8/7/2025ARVNArvinasHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$24.00 ➝ $18.008/7/2025ARVNArvinasWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$19.00 ➝ $16.008/7/2025ARVNArvinasGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$16.00 ➝ $15.007/3/2025THTXTheratechnologiesJones TradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARVNArvinas$372.80M1.52N/AN/A$8.17 per share0.95OLMAOlema PharmaceuticalsN/AN/AN/AN/A$7.14 per shareN/AOPTOpthea$30K19,437.00N/AN/A($1.31) per share-2.60THTXTheratechnologies$84.38M1.80N/AN/A($0.55) per share-6.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARVNArvinas-$198.90M-$1.01N/AN/AN/A-19.47%-12.01%-6.97%10/29/2025 (Estimated)OLMAOlema Pharmaceuticals-$129.47M-$1.98N/AN/AN/AN/A-42.58%-38.65%11/11/2025 (Estimated)OPTOpthea-$162.79MN/A0.00N/AN/AN/AN/AN/AN/ATHTXTheratechnologies-$8.31M-$0.19N/A47.14N/A-10.85%N/A-9.83%10/9/2025 (Estimated)Latest THTX, OPT, ARVN, and OLMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025OLMAOlema Pharmaceuticals-$0.43-$0.51-$0.08-$0.51N/AN/A8/6/2025Q2 2025ARVNArvinas-$0.87-$0.84+$0.03-$0.84$34.42 million$22.40 million7/9/2025Q2 2025THTXTheratechnologies-$0.01-$0.09-$0.08-$0.09$24.30 million$17.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARVNArvinasN/AN/AN/AN/AN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/AN/AOPTOptheaN/AN/AN/AN/AN/ATHTXTheratechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARVNArvinasN/A5.645.64OLMAOlema Pharmaceuticals0.0111.0911.09OPTOptheaN/A0.22N/ATHTXTheratechnologiesN/A0.840.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARVNArvinas95.19%OLMAOlema Pharmaceuticals91.78%OPTOpthea55.95%THTXTheratechnologiesN/AInsider OwnershipCompanyInsider OwnershipARVNArvinas4.73%OLMAOlema Pharmaceuticals16.36%OPTOpthea3.20%THTXTheratechnologiesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARVNArvinas42073.42 million69.95 millionOptionableOLMAOlema Pharmaceuticals7068.63 million57.41 millionOptionableOPTOpthea8171.00 million165.53 millionNot OptionableTHTXTheratechnologies14045.98 millionN/AOptionableTHTX, OPT, ARVN, and OLMA HeadlinesRecent News About These CompaniesTheratechnologies shareholders approve proposed acquisition by Future PakSeptember 12 at 3:19 PM | msn.comTheratechnologies Shareholders Approve Acquisition by Future Pak AffiliateSeptember 12 at 12:10 PM | tipranks.comTheratechnologies Shareholders Approve Proposed Plan of Arrangement to Be Acquired by Future PakSeptember 12 at 11:31 AM | financialpost.comFTheratechnologies Shareholders Approve Proposed Plan of Arrangement to Be Acquired by Future PakSeptember 12 at 11:23 AM | globenewswire.comShort Interest in Theratechnologies Inc. (NASDAQ:THTX) Expands By 31.4%September 10, 2025 | marketbeat.comTheratechnologies announces availability of EGRIFTA WRSeptember 6, 2025 | msn.comTheratechnologies Announces Availability of EGRIFTA WR™ (tesamorelin) for injection to Reduce Excess Abdominal Fat in Adults with HIV and LipodystrophySeptember 5, 2025 | globenewswire.comNantahala Capital Management LLC Cuts Stake in Theratechnologies Inc. $THTXSeptember 3, 2025 | marketbeat.comTheratechnologies Announces Independent Proxy Advisor Firms ISS and Glass Lewis Recommend Shareholders Vote “FOR” the Proposed Plan of Arrangement with Future PakSeptember 2, 2025 | globenewswire.comTheratechnologies Inc. (NASDAQ:THTX) Sees Significant Drop in Short InterestAugust 23, 2025 | marketbeat.comTheratechnologies Announces Filing of Special Meeting Materials and Receipt of Interim Order in Relation to its Acquisition by CB Biotechnology, an Affiliate of Future PakAugust 18, 2025 | globenewswire.comTheratechnologies Reports Financial Results for the Second Quarter 2025July 9, 2025 | globenewswire.comTheratechnologies: Beyond GLP-1s - Is Tesamorelin's Exit A Sign Of New Metabolic Opportunities?July 7, 2025 | seekingalpha.comFuture Pak to buy Theratechnologies for $254 millionJuly 4, 2025 | thepharmaletter.comTTheratechnologies Stock (NASDAQ:THTX), Insider Trading ActivityJuly 3, 2025 | benzinga.comTheratechnologies Inc. (THTX) - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comTheratechnologies Stock Short Interest Report | NASDAQ:THTX - BenzingaJuly 3, 2025 | benzinga.comTheratechnologies shareholders should take the deal, Research Capital saysJuly 3, 2025 | cantechletter.comCTheratechnologies to be bought by CB Biotechnology for $254MJuly 3, 2025 | msn.comTheratechnologies to Announce Second Quarter 2025 Financial ResultsJuly 3, 2025 | globenewswire.comTheratechnologies to be Acquired by Future Pak AffiliateJuly 2, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesCan Identity Security Fuel CrowdStrike’s Next Growth Phase?By Chris Markoch | August 22, 2025Smaller Industrials Names Seeing Surging Growth: Here's WhyBy Nathan Reiff | August 30, 2025Microsoft Stock: Bullish Bets Pile Up Before SeptemberBy Chris Markoch | August 18, 2025How ServiceNow Is Turning AI Strategy Into Real RevenueBy Jeffrey Neal Johnson | August 22, 2025Petrobras: Why Traders Are Betting Big on a Shareholder PayoutBy Jeffrey Neal Johnson | August 26, 2025THTX, OPT, ARVN, and OLMA Company DescriptionsArvinas NASDAQ:ARVN$7.74 -0.07 (-0.90%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$7.77 +0.03 (+0.39%) As of 09/12/2025 05:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Olema Pharmaceuticals NASDAQ:OLMA$7.77 -0.23 (-2.88%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$8.06 +0.29 (+3.73%) As of 09/12/2025 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.Opthea NASDAQ:OPT$3.41 0.00 (0.00%) As of 09/12/2025Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.Theratechnologies NASDAQ:THTX$3.30 +0.02 (+0.61%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$3.30 0.00 (-0.15%) As of 09/12/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
